Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxyurea plus dose-intense temozolomide in recurrent glioblastoma
NL-OMON20720Not yet recruiting
- Sponsor
- VU University Medical Center
- Start
- Jun 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of hydroxyurea and temozolomide in glioblastoma (GBM), sponsored by VU University Medical Center. Primary endpoints: Maximum tolerated dose and Safety profile. Planned start Jun 2016; status: not yet recruiting.
02
Drugs
hydroxyureatemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON20720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20720.